TLPH (Talphera) Cyclically Adjusted PS Ratio: (As of Jul. 09, 2026)


TLPH Talphera Inc TLPH
35 GF Score
Price $1.25
! 5 Warning Signs
View Full Analysis

What is Talphera Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Talphera  (NAS:TLPH) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Talphera Cyclically Adjusted PS Ratio Related Terms


Talphera Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Talphera's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Talphera Cyclically Adjusted PS Ratio Chart

Talphera Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.20 0.00 0.00

Talphera Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.00 0.00 0.00 0.00

TLPH vs CTOR, ETST, INCR: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Talphera's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Talphera Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Talphera's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Talphera's Cyclically Adjusted PS Ratio falls into.


TLPH
35GF Score
Talphera Inc TLPH
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Talphera Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Talphera's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Talphera's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Talphera Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 2.000 241.018 2.740
201609 1.485 241.428 2.031
201612 2.839 241.432 3.883
201703 1.371 243.801 1.857
201706 1.172 244.955 1.580
201709 0.642 246.819 0.859
201712 0.294 246.524 0.394
201803 0.135 249.554 0.179
201806 0.316 251.989 0.414
201809 0.126 252.439 0.165
201812 0.173 251.233 0.227
201903 0.067 254.202 0.087
201906 0.239 256.143 0.308
201909 0.153 256.759 0.197
201912 0.119 256.974 0.153
202003 0.096 258.115 0.123
202006 0.725 257.797 0.929
202009 0.311 260.280 0.395
202012 0.160 260.474 0.203
202103 0.090 264.877 0.112
202106 0.074 271.696 0.090
202109 0.312 274.310 0.376
202112 0.000 278.802 0.000
202203 0.000 287.504 0.000
202206 0.000 296.311 0.000
202209 0.000 296.808 0.000
202212 0.000 296.797 0.000
202303 0.000 301.836 0.000
202306 0.023 305.109 0.025
202309 0.007 307.789 0.008
202312 0.015 306.746 0.016
202403 0.000 312.332 0.000
202406 0.000 314.175 0.000
202409 0.000 315.301 0.000
202412 0.000 315.605 0.000
202503 0.001 319.799 0.001
202506 0.000 322.561 0.000
202509 0.000 324.800 0.000
202512 0.000 324.054 0.000
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Talphera Business Description

Other Exchanges R5XA:Germany
Address 1850 Gateway Drive, Suite 175, San Mateo, CA, USA, 94404
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
35GF Score

Get the complete analysis for TLPH

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.25
Price